

Available online at www.sciencedirect.com



Automatica 39 (2003) 1983-1988

\_\_\_\_\_

automatica

www.elsevier.com/locate/automatica

# Brief Paper Estimation of HIV/AIDS parameters $\stackrel{\ensuremath{\scale}}{\to}$

Xiaohua Xia\*

Department of Electrical, Electronic and Computer Engineering, University of Pretoria, Pretoria 0002, South Africa

Received 10 April 2002; received in revised form 17 December 2002; accepted 18 June 2003

## Abstract

This paper shows how well-established control system techniques can be introduced to formulate guidelines for clinical testing and monitoring of HIV/AIDS disease and the estimation of HIV/AIDS parameters. It is assumed that the viral load and healthy CD4+T cell in plasma are measured. The objective is to estimate all parameters in the basic three-dimensional HIV/AIDS model. For this purpose, through an analysis of basic system properties, the minimal number of measurement samples for the CD4+T cell and the viral load counts is first obtained. The paper determines then the HIV progression stages when an estimation of all parameters is impossible. Outside these stages, the paper proposes two on-line estimation algorithms for all HIV parameters based on the well-known techniques of adaptive identifiers and adaptive observers. Conditions for parameter convergence are discussed. Simulation results are demonstrated for the parameter estimation using adaptive observers.

© 2003 Elsevier Ltd. All rights reserved.

Keywords: Adaptive identifier; Adaptive observer; Biomedical; HIV/AIDS; Identifiability; Non-linear systems; Observability

## 1. Introduction

Over the last two decades tremendous effort has been applied to the mathematical modeling of the epidemiology and immunology dynamics of HIV (Perelson & Nelson, 1999; Nowak & May, 2000; Covert & Kirschner, 2000). There are several approaches to the modeling of the infectious diseases at the cellular level to describe the immune system and the host–pathogen interaction. These approaches give profound insights to the dynamics of the disease (Ho et al., 1995; Wei et al., 1995).

While many of the models have tended to focus on explaining the dynamics of CD4+T cells and viral load in blood, model parameters were only estimated for the virus clearance rate and the death rate of infected CD4+T cells for a post-treatment period of very strong chemotherapy in Ho et al. (1995), Wei et al. (1995), and later re-calibrated in Perelson, Neumann, Markowitz, Leonard, and Ho (1996). These estimates are very rough, because, the key assumption that inhibition is 100% effective has not been verified and is hardly practical. As for other parameters, very little attention has been given to the estimation, except for an analysis, based on the quasi-steady state or set point of the asymptomatic period before it is disturbed by chemotherapy (Wein, Zenios, & Nowak, 1997). Estimations of all these parameter in the early infection stage are necessary to predict the viral load set points, which are an important indication of disease progression. Post-treatment estimates are helpful in determining the drug efficacy.

The objective of this paper is to estimate all the parameters in the basic three-dimensional HIV/AIDS model. The minimal number of measurement samples for the CD4+T cell and the viral load counts is first obtained in Section 2. The paper determines then the HIV progression stages when an estimation of all parameters is impossible. Outside these stages, the paper proposes in Section 3 and Section 4 two on-line estimation algorithms based on the well-known techniques of adaptive identifiers and adaptive observers. Conditions for parameter convergence are discussed. Simulation results are demonstrated in Section 5 for adaptive observers. In Section 6, some conclusions are drawn.

<sup>☆</sup> The paper was presented at the 15th IFAC World Congress, Barcelona, 21–26 July 2002. This paper was recommended for publication in revised form by Associate Editor Tomas McKelvey under the direction of Editor Torsten Söderström.

<sup>\*</sup> Tel.: +44-114-222-3790; fax: +27-12-362-5000.

E-mail address: xxia@postino.up.ac.za (X. Xia).

#### 2. HIV/AIDS model and its properties

Consider the following three-dimensional model of HIV/AIDS:

$$\begin{aligned} \dot{x}_1 &= s - dx_1 - \beta x_1 x_3, \\ \dot{x}_2 &= \beta x_1 x_3 - \mu_1 x_2, \\ \dot{x}_3 &= k x_2 - \mu_2 x_3. \end{aligned} \tag{1}$$

A description of the model follows:

The first equation is the population dynamics of the uninfected CD4+T cells. Since it is a one-compartment model,  $x_1$ is identified with the CD4+T cell counts in blood per cubic millimeter. s represents the rate at which new CD4+T cells are created from sources within the body, such as the thymus. T cells can also be created by proliferation of existing T cells. A proliferation term can be added to the right-hand side (Perelson, Kirschner, & De Boer, 1993; Kirschner, Lenhart, & Serbin, 1997; Perelson & Nelson, 1999; Alvarez-Ramirez, Meraz, & Velasco-Hernandez, 2000). Some authors assume, however, that the source term s is constant, and the proliferation effect may be lumped into the constant d (see Nowak & May, 2000 and references therein). In this paper, the proliferation term is not considered separately for simplicity reasons. In the presence of HIV, T cells become infected. This infection is represented by a "mass-action" term in which the rate of infection is given by  $\beta x_1 x_3$ , with  $\beta$  being the infection rate constant.  $x_3$  is explained below.

The second equation is the population dynamics of the infected cells. Infected cells are produced at a rate of  $\beta x_1 x_3$  from the infection of healthy cells by HIV.  $\mu_1 x_2$  is the death rate of infected cells.

The last equation represents the dynamics of the concentration of free virions. The free virions are produced by the infected CD4+T cells at a rate constant k, and  $\mu_2 x_3$  is the death rate of free virions. In this equation, the loss of virus due to infection of a cell is ignored.

This basic model has been considered in Nowak and Bangham (1996), Nowak and May (2000), Perelson and Nelson (1999). To reveal more detailed progression of the disease, the model has also been extended to higher dimensions in Perelson et al. (1993), Kirschner et al. (1997), Perelson and Nelson (1999), Alvarez-Ramirez et al. (2000), Nowak and May (2000). The identifiability properties of some higher dimensional models will be discussed elsewhere.

Clinically, all the above three variables can be measured. The cost of quantifying the infected cells is much higher. In this paper, it is assumed that the measurement of the viral load and the healthy CD4+T cell counts in plasma is available. That is, the measured outputs are  $y_1 = x_1$  and  $y_2=x_3$ . It will be shown that the measurement of the infected CD4+T cells is unnecessary to estimate the parameters of the model. A variance of 20 copies per cubic millimeter for T cell counts and a log-variance of 0.2 for viral load are normal measurement variance as described in CDC Working Group (2003).

Observability (identifiability) is a basic system property of whether all state variables (all parameters) can be calculated from the measured output. In this paper, the precise meaning of observability and identifiability is understood as in Conte, Moog, and Perdon (1999), Ljung and Glad (1994). System (1) is both observable and identifiable, as was shown in Xia and Moog (2003).

Identifiability means that all parameters can be determined from the measured output. To find the conditions under which parameters can actually be determined, higherorder differential equations of the output can be calculated as

$$\dot{y}_1 = \theta_1 + \theta_2 y_1 + \theta_3 y_1 y_2,$$
 (2)

$$\ddot{y}_2 = \theta_4 \dot{y}_2 + \theta_5 y_2 + \theta_6 y_1 y_2, \tag{3}$$

where

$$\boldsymbol{\varTheta} = \begin{bmatrix} \theta_1 \\ \theta_2 \\ \theta_3 \\ \theta_4 \\ \theta_5 \\ \theta_6 \end{bmatrix} = \begin{bmatrix} s \\ -d \\ -\beta \\ -\mu_1 - \mu_2 \\ -\mu_1 \mu_2 \\ k\beta \end{bmatrix}.$$

 $\Theta$  defines a one-to-one map for  $\beta \neq 0$  and  $\mu_1 \neq \mu_2$ . It is known that for most HIV patients,  $\beta \neq 0$  and  $\mu_2 > \mu_1$ (Nowak & May, 2000). In this case, it has the following inverse map:

$$\begin{bmatrix} s \\ d \\ \beta \\ \mu_1 \\ \mu_2 \\ k \end{bmatrix} = \begin{bmatrix} \theta_1 \\ -\theta_2 \\ -\theta_3 \\ \frac{-\theta_4 - \sqrt{\theta_4^2 + 4\theta_5}}{2} \\ \frac{-\theta_4 + \sqrt{\theta_4^2 + 4\theta_5}}{2} \\ \frac{-\theta_4 + \sqrt{\theta_4^2 + 4\theta_5}}{2} \\ -\frac{\theta_6}{\theta_3} \end{bmatrix}.$$
 (4)

From Eq. (4), the identification of the original parameters of (1) is equivalent to that of  $\Theta$ .

Therefore, it is necessary to generate a minimum of six equations based on (2) and (3), three from each equation. This will be achieved by differentiating (2) and (3) two more times, resulting derivatives of  $y_1$  and  $y_2$  up to the order of 3 and 4, respectively. To cope with these order of derivatives, one concludes that at least four measurements of the CD4+T cell count  $y_1$  and five measurements of the viral load are needed for a complete determination of all the HIV/AIDS parameters in the 3-dimensional model (1).

For simplicity, assume that the following measurements are available:

$$y_1^0 = y_1(t_0), \qquad y_1^1 = y_1(t_0 + d_1),$$
  

$$y_1^2 = y_1(t_0 + d_1 + d_2), \qquad y_1^3 = y_1(t_0 + d_1 + d_2 + d_3),$$
  

$$y_2^0 = y_2(t_0), \qquad y_2^1 = y_2(t_0 + d_1),$$
  

$$y_2^2 = y_2(t_0 + d_1 + d_2), \qquad y_2^3 = y_2(t_0 + d_1 + d_2 + d_3),$$
  

$$y_2^4 = y_2(t_0 + d_1 + d_2 + d_3 + d_4).$$

From these measurements, the following three equations can be generated based on (2), in which the derivative of  $y_1$  is approximated by  $\Delta y_1/\Delta t$ .

$$A\begin{bmatrix} \theta_1\\ \theta_2\\ \theta_3 \end{bmatrix} = \begin{bmatrix} 1 & y_1^0 & y_1^0 y_2^0\\ 1 & y_1^1 & y_1^1 y_2^1\\ 1 & y_1^2 & y_1^2 y_2^2 \end{bmatrix} \begin{bmatrix} \theta_1\\ \theta_2\\ \theta_3 \end{bmatrix} = \begin{bmatrix} \frac{y_1^1 - y_1^0}{d_1}\\ \frac{y_1^2 - y_1^1}{d_2}\\ \frac{y_1^3 - y_1^2}{d_3} \end{bmatrix}.$$

If the matrix A is non-singular, then there is a unique solution for  $\theta_1, \theta_2$  and  $\theta_3$ , and hence estimates for s, d and  $\beta$ . These are essentially least-square (LSQ) estimates.

On the other hand, when either  $y_1$  or  $y_2$  is constant, then A can never be non-singular for any choice of measurement interval. In the long asymptomatic stage, the viral load  $y_2$  remains constant, and in the short period after chemotherapy treatment, the CD4+T cell count does not change much (see the assumption made in Ho et al. (1995)). Wei et al. (1995)). Therefore during these two time periods, a complete determination of s, d and  $\beta$  is impossible.

Similar conclusions can be drawn from (3) for the estimates of  $\mu_1$ ,  $\mu_2$  and k.

Of course, this orthodox pure LSQ would fail with noisy measurement. One way to overcome this is to use improved versions of LSQ method. Another way is to use adaptive algorithms.

### 3. Estimation using adaptive identifiers

It is a standard practice in adaptive estimation to design a suitable filter for the available signals (Sastry & Bodson, 1989).

Let

$$\lambda_1(s) = s + \lambda_{11},$$
  
 $\lambda_2(s) = s^2 + \lambda_{22}s + \lambda_{21},$ 

be two Hurwitz polynomials, i.e.,  $\lambda_{11}$ ,  $\lambda_{21}$  and  $\lambda_{22}$  are all positive. Denote the Laplace transforms of  $y_1(t)$ ,  $y_2(t)$  and  $y_1(t)y_2(t)$  as  $y_1(s)$ ,  $y_2(s)$  and  $\overline{y_1y_2}(s)$ , respectively.

Then from (2) and (3),

$$y_{1}(s) = \frac{1}{\lambda_{1}(s)} \phi_{11} + \frac{y_{1}(s)}{\lambda_{1}(s)} \phi_{21} + \frac{\overline{y_{1}y_{2}(s)}}{\lambda_{1}(s)} \phi_{31},$$
  
$$y_{2}(s) = \frac{sy_{2}(s)}{\lambda_{2}(s)} \phi_{12} + \frac{y_{2}(s)}{\lambda_{2}(s)} \phi_{22} + \frac{\overline{y_{1}y_{2}(s)}}{\lambda_{2}(s)} \phi_{32},$$

where the new parameterization is

$$egin{aligned} \Phi &= egin{bmatrix} \phi_{11} & \phi_{12} \ \phi_{21} & \phi_{22} \ \phi_{31} & \phi_{32} \end{bmatrix} = egin{bmatrix} heta_1 & \lambda_{22} + heta_4 \ \lambda_{11} + heta_2 & \lambda_{21} + heta_5 \ heta_3 & heta_6 \end{bmatrix}. \end{aligned}$$

Define the following time-domain realizations:

$$\begin{split} \dot{\xi}_1 &= -\lambda_{11}\xi_1 + 1, \\ \dot{\xi}_2 &= -\lambda_{11}\xi_2 + y_1, \\ \dot{\xi}_3 &= -\lambda_{11}\xi_3 + y_1y_2, \\ \dot{\xi}_{21} &= \xi_{22}, \\ \dot{\xi}_{22} &= -\lambda_{21}\xi_{21} - \lambda_{22}\xi_{22} + y_2, \\ \dot{\xi}_{31} &= \xi_{32}, \\ \dot{\xi}_{32} &= -\lambda_{21}\xi_{31} - \lambda_{22}\xi_{32} + y_1y_2 \end{split}$$

and denote

$$W = \begin{bmatrix} w_{11} & w_{12} \\ w_{21} & w_{22} \\ w_{31} & w_{32} \end{bmatrix} = \begin{bmatrix} \xi_1 & \xi_{22} \\ \xi_2 & \xi_{21} \\ \xi_3 & \xi_{31} \end{bmatrix},$$

and one can define the following identifier output:

$$Y_i(t) = \begin{bmatrix} y_{i1}(t) \\ y_{i2}(t) \end{bmatrix} = \Phi^{\mathrm{T}} W(t),$$
(5)

and the identifier error

$$E(t) = \begin{bmatrix} e_1(t) \\ e_2(t) \end{bmatrix} = Y_i(t) - Y(t), \tag{6}$$

in which

$$Y(t) = \begin{bmatrix} y_1(t) \\ y_2(t) \end{bmatrix}$$

Then the parameter updating law is given by the following standard gradient algorithm:

$$\dot{\Phi} = -[g_1 e_1(t) W_1(t) \quad g_2 e_2(t) W_2(t)] \tag{7}$$

in which,  $g_1 > 0$  and  $g_2 > 0$ .

An alternative is the normalized gradient algorithm

$$\dot{\Phi} = -\left[\frac{g_1 e_1(t) W_1(t)}{1 + \gamma_1 W_1^{\mathrm{T}} W_1} \quad \frac{g_2 e_2(t) W_2(t)}{1 + \gamma_2 W_2^{\mathrm{T}} W_2}\right],\tag{8}$$

in which  $W_1(t), W_2(t)$  are the columns of W(t), and  $\gamma_1 > 0$ and  $\gamma_2 > 0$ .

In any case,  $Y_i(t)$  approaches Y(t). In order for the parameters to converge (Sastry & Bodson, 1989), it is necessary for the vector  $\overline{W}(t) = (w_{11}(t), w_{21}(t), w_{31}(t), w_{12}(t), w_{22}(t), w_{22}(t), w_{31}(t), w_{31}(t), w_{32}(t), w_{32}(t), w_{33}(t), w_{33$  $w_{32}(t)$ <sup>T</sup> to be persistently exciting (PE). Note that the transfer function from  $\overline{u} = (1, y_1(t), y_2(t), y_1(t)y_2(t))^T$ to  $\overline{W}(t)$  is

$$H(s) = \begin{bmatrix} \frac{1}{\lambda_{1}(s)} & 0 & 0 & 0\\ 0 & \frac{1}{\lambda_{1}(s)} & 0 & 0\\ 0 & 0 & 0 & \frac{1}{\lambda_{1}(s)}\\ 0 & 0 & \frac{s}{\lambda_{2}(s)} & 0\\ 0 & 0 & \frac{1}{\lambda_{2}(s)} & 0\\ 0 & 0 & 0 & \frac{1}{\lambda_{2}(s)} \end{bmatrix}.$$
 (9)

Decomposing  $\overline{W}(t)$  into  $\overline{W}^1(t) + \overline{W}^2(t)$  such that

 $\bar{W}(s) \stackrel{\text{def}}{=} \bar{W}^1(s) + \bar{W}^2(s)$ 

 $\stackrel{\text{def}}{=} H^1(s)\bar{u}(s) + (0,0,0,v_2(s),0,0)^{\mathrm{T}}.$ 

The following two assumptions are made:

**Assumption 1.**  $\bar{u}(t) = (1, y_1(t), y_2(t), y_1(t)y_2(t))^T$  satisfy  $\int_{0}^{t+1} \bar{u}(\tau) \bar{u}(\tau)^{\mathrm{T}} \,\mathrm{d}\tau \ge k > 0,$ 

*i.e.*, the persistent excitation condition is satisfied for some T > 0, and every  $t \ge 0$ .

**Assumption 2.**  $y_2(t) \in L_2$ , that is, the viral load is a square integrable function of time.

Since  $H^1(s)$  is stable, minimum phase and rational, by Assumption 1 and Lemma 2.6.7 of Sastry and Bodson (1989),  $\overline{W}^{1}(t)$  is PE. By Assumption 2 and Lemma 2.6.6 of Sastry and Bodson (1989),  $\overline{W}(t)$  is PE.

The technical Assumptions 1 and 2 may not be easily met in practice (for every t > 0), but it helps to indicate the most likely period for a complete estimation of parameters. An intuitive interpretation of the above analysis is that when the curve of  $y_1$  and  $y_2$  are bent enough and "the cumulated strength of the virus"  $(y_2)$  is bounded, all six parameters can be estimated with confidence of accuracy. Two such typical phases in HIV/AIDS progression are the primary infection

stage and the period after chemotherapy treatment, whenboth the viral load and CD4+T cell counts are changing.

Coincidentally, one notices that all previous estimations of the virus clearance rate  $(\mu_2)$  and the death rate of infected cell  $(\mu_1)$  were made for a post-treatment period of very strong chemotherapy using reverse transcriptor inhibitors and protease inhibitors (Ho et al., 1995; Wei et al., 1995; Perelson et al., 1996). This choice becomes obvious from the above analysis of parameter convergence.

#### 4. Estimation using adaptive observers

It will be shown in this section that adaptive observers of the Marino-Tomei type (Marino & Tomei, 1995) provide another globally convergent parameter estimator. Refer to Marino and Tomei (1995, 2000), Xia (2000) for details of the design and some recent applications of adaptive observers.

The procedures for designing adaptive observer estimators is described as follows:

For system (1), let  $z_1 = x_1$ ,  $z_2 = kx_2 + \mu_1 x_3$ ,  $z_3 = x_3$ , when  $k \neq 0$ , this transformation is invertible, and system (1) can be transformed into the following observer form:

$$\dot{z}_1 = \theta_1 + \theta_2 y_1 + \theta_3 y_1 y_2,$$
  

$$\dot{z}_2 = \theta_6 y_1 y_2 + \theta_5 y_2,$$
  

$$\dot{z}_3 = z_2 + \theta_4 y_2,$$
 (10)  

$$y_1 = z_1,$$
  

$$y_2 = z_3.$$
  
Define the filtered transformation

 $\eta_1 = z_1,$ 

~

$$\eta_{2} = z_{2} - \theta_{6}\xi_{1} - \theta_{5}\xi_{2} - \theta_{4}\xi_{3},$$
  

$$\eta_{3} = z_{3}$$
  
in which  

$$\dot{\xi}_{1} = -b\xi_{1} + y_{1}y_{2},$$
  

$$\dot{\xi}_{2} = -b\xi_{2} + y_{2},$$
  

$$\xi_{3} = -b\xi_{2},$$

with b > 0, then the system can be transformed into an adaptive observer form:

$$\begin{split} \dot{\eta}_1 &= \theta_1 + \theta_2 y_1 + \theta_3 y_1 y_2, \\ \dot{\eta}_2 &= b[\theta_6 \xi_1 + \theta_5 \xi_2 + \theta_4 (\xi_3 + y_2)], \\ \dot{\eta}_3 &= \eta_2 + [\theta_6 \xi_1 + \theta_5 \xi_2 + \theta_4 (\xi_3 + y_2)], \\ y_1 &= \eta_1, \\ y_2 &= \eta_3. \end{split}$$
(11)

An adaptive observer can then be designed as the following:

$$\dot{\hat{\eta}}_{1} = k_{1}\hat{\eta}_{1} + \hat{\theta}_{1} + \hat{\theta}_{2}y_{1} + \hat{\theta}_{3}y_{1}y_{2} - k_{1}y_{1},$$
  
$$\dot{\hat{\eta}}_{2} = k_{2}\hat{\eta}_{3} + b[\hat{\theta}_{6}\xi_{1} + \hat{\theta}_{5}\xi_{2} + \hat{\theta}_{4}(\xi_{3} + y_{2})] - k_{2}y_{2},$$
  
$$\dot{\hat{\eta}}_{3} = k_{3}\hat{\eta}_{3} + \hat{\eta}_{2} + [\hat{\theta}_{6}\xi_{1} + \hat{\theta}_{5}\xi_{2} + \hat{\theta}_{4}(\xi_{3} - y_{2})] - k_{3}y_{2},$$
  
(12)

$$\begin{vmatrix} \hat{\theta}_1 \\ \hat{\theta}_2 \\ \hat{\theta}_3 \end{vmatrix} = \Gamma_1 \begin{bmatrix} 1 \\ y_1 \\ y_1 y_2 \end{bmatrix} (y_1 - \hat{\eta}_1), \tag{13}$$

$$\begin{bmatrix} \dot{\hat{\theta}}_4 \\ \dot{\hat{\theta}}_5 \\ \dot{\hat{\theta}}_6 \end{bmatrix} = \Gamma_2 \begin{bmatrix} y_2 + \xi_3 \\ \xi_2 \\ \xi_1 \end{bmatrix} (y_2 - \hat{\eta}_3), \tag{14}$$

where  $\Gamma_1, \Gamma_2$  are symmetric positive definite matrices,  $k_1$  is any negative number,  $k_2 = -b$  and  $k_3 = -b - \lambda$  for  $\lambda > 0$ .

The estimation of the original parameters can be determined by the estimation of  $\theta$  through (4).

The convergence of parameters using adaptive observers can be discussed along similar lines as for adaptive identifiers, and it is omitted due to space limitation. It can be noted that the parameter convergence conditions for adaptive observers are the same as for adaptive identifiers.

## 5. Simulation

The simulation is carried out in the Matlab/Simulink environment. Results are shown only for parameter estimation using adaptive observers.

Assume that the model has the following parameters: s = 7, d = 0.007,  $\beta = 0.0000042163$ ,  $\mu_1 = 0.0999$ ,  $\mu_2 = 0.2$ , k = 90.67.

Using these parameters, the HIV progression is depicted in Fig. 1. It can be noted that this set of parameters corresponds to a typical HIV infection and progression over four years. After the initial infection, the healthy CD4+T cell drops from the usual 1000 per cubic millimeter to less than four hundred in about four months' time. The viral load increases dramatically in the acute infection stage and peaks at about three months after infection. A set point is reached after about five hundred days.

Since the numerical values of the CD4+T count and the virus load are not in the same order of magnitude, the variables are first normalized in the simulation. The adaptive observer is chosen to start from day 225 after infection. This choice is arbitrary subject to the condition that the signals are sufficiently excited. To test the algorithm against measurement noise, zero mean random signals with variance of 20 and log variance of 0.2 are added to  $y_1$  and  $y_2$ ,



Fig. 1. Typical HIV infection and progression.



Fig. 2. Estimation HIV/AIDS parameters, solid: without measurement noise; dash: with measurement noise.

respectively. The results are demonstrated in Fig. 2. It can be found from these results that very good estimations can be obtained using about 3 months' data. It can also be found that the estimates of *s*, *d*,  $\beta$  and *k* are relatively smooth, while the estimations of  $\mu_1$  and  $\mu_2$  undergo some fluctuations. This phenomenon is in accordance with the fact that virus and infected cells have a very rapid turnover (Ho et al., 1995; Wei et al., 1995).

# 6. Conclusion

In this paper, the problem of estimating all parameters in the basic HIV/AIDS model is studied by making use of well-established control system techniques. Through an analysis of basic system properties, the minimal number of sample measurement for the CD4+T cell and the viral load was obtained for a complete model parameter estimation. The HIV progression stages, when an estimation of all parameters is impossible, were then determined. Outside these stages, on-line estimations of all parameters were given based on two well-known techniques in control theory: adaptive identifiers and adaptive observers. Conditions for parameter convergence were discussed. Simulation results were shown for the adaptive observers.

This study enables one to formulate the following guidelines for the clinical testing and monitoring, as far as the estimation of all six HIV/AIDS parameters in the basic model is concerned:

- At least four measurements of CD4+T cell count and five measurements of viral load are needed for a complete determination of all the HIV/AIDS parameters;
- (2) In the asymptomatic stage of HIV, a complete determination of all parameters is impossible;
- (3) In the short period after chemotherapy treatment when the CD4+T cell count does not change much, a complete determination of all parameters is impossible;
- (4) It is most probable to determine all parameters in the early infection stage;
- (5) All parameters can be estimated by sufficiently disturbing the set point in the asymptomatic stage of HIV using effective anti-retrovirus drugs.

Remaining issues to be investigated include the clinical data verification. For this purpose, the assumption that daily blood samples are available is of course not very practical. Interpolation must be implemented. In practice, samples are sometimes taken more frequently, e.g., hourly (Perelson & Nelson, 1999), especially after treatment. This will certainly improve the efficiency of the estimation.

Estimation algorithms will be useful in the study of clinical drug resistance, since resistance can be represented by the fact that the parameters  $\beta$  and/or k become smaller. A quantitative study about resistance can be given by detecting the changes of the estimates of  $\beta$  and k.

### References

- Alvarez-Ramirez, J., Meraz, M., & Velasco-Hernandez, J. X. (2000). Feedback control of the chemotherapy of HIV. *International Journal* of Bifurcation and Chaos, 10, 2207–2219.
- CDC Working Group (2003). Guidelines for laboratory test result reporting of human immunodeficiency virus type i ribonucleic acid determination. [on-line], http://www.cdc.gov/.
- Conte, G., Moog, C. H., & Perdon, A. M. (1999). Nonlinear control systems: An algebraic setting. London: Springer.

- Covert, D., & Kirschner, D. (2000). Revisiting early models of the host-pathogen interactions in HIV infection. *Comments Theoretical Biology*, 5, 383–411.
- Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature*, 273, 123–126.
- Kirschner, D., Lenhart, S., & Serbin, S. (1997). Optimal control of the chemotherapy of HIV. *Journal of Mathematical Biology*, 35, 775–792.
- Ljung, L., & Glad, T. (1994). On global identifiability for arbitrary model parameterizations. *Automatica*, 30, 265–276.
- Marino, R., & Tomei, P. (1995). Nonlinear control design: Geometric, adaptive and robust. New York: Prentice-Hall.
- Marino, R., & Tomei, P. (2000). Global estimation of *n* unknown frequencies. *IEEE 39th conference on decision and control*, Sydney, Australia (pp. 1143–1147).
- Nowak, M. A., & Bangham, C. R. M. (1996). Population dynamics of immune responses to persistent viruses. *Science*, 272, 74–79.
- Nowak, M. A., & May, R. M. (2000). Virus dynamics: Mathematical principles of immunology and virology. New York: Oxford University Press.
- Perelson, A. S., Kirschner, D., & De Boer, R. (1993). Dynamics of HIV infection of CD4+T cells. *Mathematical Biosciences*, 114, 81–125.
- Perelson, A. S., & Nelson, P. W. (1999). Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review, 41, 3–44.
- Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. *Science*, 271, 1582–1586.
- Sastry, S., & Bodson, M. (1989). Adaptive control: Stability, convergence, and robustness. London: Prentice-Hall.
- Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J.D., et al. (1995). Viral dynamics in HIV-1 infection. *Nature*, 273, 117–122.
- Wein, L. M., Zenios, S. A., & Nowak, M. A. (1997). Dynamic multidrug therapies for HIV: A control theoretic approach. *Journal of Theoretical Biology*, 185, 15–29.
- Xia, X. (2000). Global frequency estimators through Marino-Tomei observers. In I. K. Craig, & F. R. Camisani-Calzolari (Eds.), *Proceedings of IFAC conference on technology transfer in developing countries: Automation in infrastructure creation*, Pretoria, South Africa (pp. 229–232), July 2000. Oxford, UK: Pergamon.
- Xia, X., & Moog, C. H. (2003). Identifiability of nonlinear systems with application to HIV/AIDS models. *IEEE Transactions on Automatic Control*, 48, 330–336.



Xiaohua Xia, obtained his D.Eng at Beijing University of Aeronautics and Astronautics, Beijing, China in 1989. After working for 5 years in the same university after PhD, he went to University of Stuttgart as an Alexander von Humboldt fellow for about two years. He made two short stays in Ecole Centrale de Nantes/France and National University of Singapore during the period of two years from 1996 to 1997, both as a post-doctoral fellow. He joined the University of Pretoria since 1998 first

as an Associate Professor then a full Professor. He also held a visiting position as an invited Professor at Ecole Centrale de Nantes/France in 2001. Dr. Xia is a Senior IEEE member, is currently the South African IEEE Section/Control Chapter Chair. He also serves for IFAC as the vice-chair of the Technical Committee of Non-linear Systems, and an Associate Editor of Automatica. His research interests include: non-linear feedback control, observer design, time-delay systems, hybrid systems, very recently control applications to HIV/AIDS. He is supported as scientist (B classification) by the National Research Foundation of South Africa.